Maximus, Inc. $MMS Shares Purchased by QRG Capital Management Inc.

QRG Capital Management Inc. increased its position in shares of Maximus, Inc. (NYSE:MMS) by 14.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,172 shares of the health services provider’s stock after acquiring an additional 886 shares during the period. QRG Capital Management Inc.’s holdings in Maximus were worth $503,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of MMS. AQR Capital Management LLC grew its holdings in Maximus by 177.2% during the first quarter. AQR Capital Management LLC now owns 1,173,329 shares of the health services provider’s stock worth $79,341,000 after acquiring an additional 750,031 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in Maximus by 40.0% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,729,305 shares of the health services provider’s stock worth $117,921,000 after acquiring an additional 494,372 shares during the period. Boston Partners acquired a new position in Maximus during the first quarter worth about $20,983,000. Dimensional Fund Advisors LP boosted its position in shares of Maximus by 20.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,695,582 shares of the health services provider’s stock valued at $115,620,000 after purchasing an additional 288,990 shares during the period. Finally, Nuveen LLC acquired a new position in shares of Maximus in the 1st quarter valued at $18,586,000. 97.21% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Maximus

In other news, insider Michelle F. Link sold 1,610 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total transaction of $146,284.60. Following the completion of the sale, the insider directly owned 13,508 shares of the company’s stock, valued at $1,227,336.88. This trade represents a 10.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

Maximus Stock Down 3.2%

MMS opened at $85.43 on Friday. Maximus, Inc. has a fifty-two week low of $63.77 and a fifty-two week high of $93.73. The business has a 50-day moving average of $86.71 and a 200-day moving average of $76.09. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.27 and a quick ratio of 2.27. The company has a market capitalization of $4.81 billion, a PE ratio of 15.73 and a beta of 0.57.

Maximus (NYSE:MMS) last posted its quarterly earnings results on Thursday, August 7th. The health services provider reported $2.16 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.77. Maximus had a return on equity of 24.44% and a net margin of 5.83%.The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the business earned $1.74 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. Equities research analysts forecast that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.4%. Maximus’s dividend payout ratio (DPR) is 22.10%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Zacks Research upgraded Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 26th. Weiss Ratings upgraded Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $90.00.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.